| Information regarding pharmacokinetic/pharmacodynamic (PK/PD) properties of hydroxychloroquine (HCQ) against SARS-CoV-2 are lacking. |
| This review describes the current understanding of PK/PD properties and dose selection of HCQ against SARS-CoV-2. |
| This review also discusses knowledge gaps that are needed to optimize efficacy/safety of treatments against COVID-19. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.